Polymer Manufacturer Invibio Settles Monopoly Claims
The US Federal Trade Commission said the company, which supplies more than 90% of a certain type of high-quality plastic used in medical implants, used exclusivity clauses in its contracts to keep competitors out of the market and illegally maintain its monopoly. An FTC final consent order was announced July 14.
You may also be interested in...
Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.
Increasing savvy around cybersecurity issues is driving regulators and trade groups to update their approach to the area, speakers from the US FDA and the American Medical Association said at this week’s FDA/CMS Summit.
The US FDA released one device-related close-out letter in November.